Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13295604 | 0.87 | MAPK1 (0.56) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13002017 | 0.86 | MAPK1 (0.41) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13313399 | 0.86 | MAPK1 (0.55) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL3767045 | 0.85 | MAPK1 (0.41) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13304565 | 0.85 | RAB9A (0.51) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13295585 | 0.84 | MAPK1 (0.53) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13057305 | 0.82 | MAPK1 (0.58) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL13057304 | 0.82 | MAPK1 (0.55) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL8521192 | 0.81 | MAPK1 (0.51) | MAPK1HSD17B10KMT2ANPC1RAB9A | |
| SCHEMBL3247151 | 0.81 | PKM (0.39) | MAPK1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847108-B2 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | BAYER CROPSCIENCE AG (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-1599460-B1 | OXATHIIN CARBOXAMIDE | BAYER CROPSCIENCE AG (DE) | 2007-11-07 | — | — | EP | disclosed |
| US-20070004793-A1 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| EP-1599460-A2 | OXATHIIN CARBOXAMIDE | Bayer CropScience Aktiengesellschaft (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004072023-A2 | OXATHIIN CARBOXAMIDE | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004793-A1 | such as N-[2-(4-bromophenyl)phenyl]-6-trifluoromethyl-2,3-dihydro-1,4-oxathiine-5-carboxamide, used for controlling unwanted microorganisms, for example, bacteria, fungi, yeasts, algae and slime organisms | Q6ZSR9, PFAS, NIT2 | MAPK1 3590/4885HSD17B10 3877/4885KMT2A 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.